PARIS, Oct. 11, 2022 /PRNewswire/ Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform
PARIS, Sept. 16, 2022 /PRNewswire/ Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform
/PRNewswire/ Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug.
EO2401 is a first-in-class OncoMimics therapeutic cancer vaccine able to significantly expand existing effector memory CD8+ T cells directed at OncoMimics peptides corresponding to tumor-associated
Enterome is evaluating EO2401 in Phase 1/2 clinical trials in recurrent glioblastoma (ROSALIE) and adrenocortical malignancies (SPENCER) Proof-of-concept data.